Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Neoplasms

Treatments: Drug: BMS-754807

Study type: Interventional

Funder types: Industry

Identifiers

NCT00898716

CA191-003

Details and patient eligibility

About

The purpose of this clinical study is to establish the maximum tolerated dose of BMS-754807 when administered orally on a once daily schedule in subjects with solid tumors.

Enrollment: 15 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
• Life expectancy of at least 3 months
• Eastern Cooperative Oncology Group performance 0-1

Exclusion criteria

• Any disorder with dysregulation of glucose homeostasis
• Dumping syndrome
• History of glucose intolerance

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

BMS-754807

Experimental group

Treatment:

Drug: BMS-754807